Last edition
News about "Bristol Myers Squibb"
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 results showing that mezigdomide reduced the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma, marking the first successful Phase 3 CELMoD trial presented at ASCO 2026.
Bristol Myers Squibb | 30/05/2026 | By News Bureau
Tempus AI Expands Strategic Partnership with Bristol Myers Squibb
Tempus AI expands its collaboration with Bristol Myers Squibb to use Artificial Intelligence (AI) and real-world data for optimising oncology and neuroscience clinical trials and improving regulatory success rates.
Bristol Myers Squibb | 15/05/2026 | By News Bureau | 218
Bristol Myers Squibb and Hengrui Pharma collaborated to jointly develop 13 early-stage programmes across oncology, haematology and immunology, with a potential deal value of up to USD 15.2 billion.
Bristol Myers Squibb | 13/05/2026 | By News Bureau
Bristol Myers Squibb Secures EC Approval for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb receives European Commission (EC) approval for Sotyktu to treat active psoriatic arthritis in adults, marking the EU’s first approved TYK2 inhibitor for this indication.
Bristol Myers Squibb | 12/05/2026 | By News Bureau
Atrium Therapeutics receives a USD 15 million milestone payment from Bristol Myers Squibb under a global collaboration to develop innovative RNA-based therapies for cardiovascular diseases.
Bristol Myers Squibb | 24/04/2026 | By News Bureau
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Trial Results
Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM results showing Camzyos efficacy and safety in adolescents with oHCM, achieving significant LVOT reduction with no new safety concerns.
Bristol Myers Squibb | 30/03/2026 | By News Bureau | 102
US FDA Clears Sotyktu for Active Psoriatic Arthritis
The US Food and Drug Administration (FDA) has approved Sotyktu, developed by Bristol Myers Squibb, for adults with active psoriatic arthritis. The once-daily oral TYK2 inhibitor showed significantly higher ACR20 response rates versus placebo in the phase-III POETYK PsA-1 and PsA-2 trials.
Bristol Myers Squibb | 07/03/2026 | By News Bureau | 117
Bristol Myers Squibb Reports Positive Phase II Data for Reblozyl in Alpha-Thalassemia
Bristol Myers Squibb’s Phase II trial shows Reblozyl significantly improved haemoglobin levels in non-transfusion-dependent patients and reduced transfusion burden in transfusion-dependent alpha-thalassemia, meeting all primary and key secondary endpoints.
Bristol Myers Squibb | 25/02/2026 | By News Bureau | 173
Iberdomide, an investigational oral CELMoD therapy, is under FDA review in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma.
Bristol Myers Squibb | 19/02/2026 | By News Bureau | 140
OXB Signs Multi-Year Commercial Supply Deal with Bristol Myers Squibb
Oxford Biomedica will serve as the commercial manufacturer of lentiviral vectors for Bristol Myers Squibb’s CAR-T programmes under a new multi-year supply agreement, which includes a five-year initial term with an option to extend.
Bristol Myers Squibb | 05/02/2026 | By News Bureau | 231
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy